Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase 1b/2, open-label, multicenter, randomized clinical trial to evaluate the safety, tolerability, pharmacokinetics and preliminary anti-tumor activity of PEGPH20 in combination with atezolizumab compared with the standard chemotherapy regimens in patients with previously treated, locally advanced unresectable or metastatic gastric or gastroesophageal junction cancer

Trial Profile

A phase 1b/2, open-label, multicenter, randomized clinical trial to evaluate the safety, tolerability, pharmacokinetics and preliminary anti-tumor activity of PEGPH20 in combination with atezolizumab compared with the standard chemotherapy regimens in patients with previously treated, locally advanced unresectable or metastatic gastric or gastroesophageal junction cancer

Status: Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 26 Oct 2017

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Atezolizumab (Primary) ; Hyaluronidase (Primary)
  • Indications Gastric cancer; Oesophageal cancer
  • Focus Adverse reactions; Pharmacokinetics
  • Sponsors Genentech
  • Most Recent Events

    • 26 Oct 2017 New trial record
    • 24 Oct 2017 According to a Halozyme Therapeutics media release, the study will be conducted in the U.S., as well as countries outside the U.S. The overall analysis plan includes a retrospective analysis of the HA-high population identified using the Ventana HA companion diagnostic assay.
    • 24 Oct 2017 According to a Halozyme Therapeutics media release, first gastric cancer patient has been dosed in the trial.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top